Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1361-1372
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Figure 1 SVR12 in the immediate treatment arm.
1Includes the patient with genotype 1a infection; 2On-treatment HCV RNA ≥ LLOQ after < LLOQ, or increased > 1 log10 over nadir; 3Posttreatment HCV RNA ≥ LLOQ after < LLOQ without detectable target at EOT. EOT: End of treatment; HCV: Hepatitis C virus; LLOQ: Lower limit of quantitation; SVR12: Sustained virologic response at post-treatment week 12.
- Citation: Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1361